title: [Expression of TFPI-2 gene in pancreatic carcinoma and its prognostic significance].
abstract: OBJECTIVE
  To detect the expression of TFPI-2 gene in pancreatic carcinoma, and to evaluate its prognostic significance in patients with pancreatic carcinoma.
  
  
  METHODS
  Reverse transcription polymerase chain reaction (RT-PCR) and Western blot were used to detect the expression of TFPI-2 mRNA and protein in the pancreatic carcinoma tissue samples from 41 patients. The correlation of its expression with clinicopathological features and its prognostic significance were analyzed.
  
  
  RESULTS
  The expression of TFPI-2 mRNA and protein in moderately or poorly differentiated pancreatic carcinoma tissues, or in cases with nerve-involvement, lymph node and blood vessel invasion was significantly lower than that in the highly differentiated one, or without nerve involvement, or neither lymphatic nor blood vessel invasion (P < 0.05). The median survival time of patients with high expression of TFPI-2 (12.0 months) was significantly longer than that with low expression of TFPI-2 (5.1 months, P < 0.05). The Cox model analysis showed that the expression of TFPI-2 was an independent marker for prognosis in patients with pancreatic carcinoma.
  
  
  CONCLUSIONS
  The expression of TFPI-2 is correlated with clinical stage and differentiation of pancreatic carcinoma, and can be used as a prognostic marker for pancreatic carcinoma.
authors.affiliation: Department of General Surgery, Anhui Provincial Hospital, Hefei 230001, China. tzg7031@163.com
authors.forename: Zhi-gang
authors.initials: ZG
authors.lastname: Tang
authors.forename: Zhen-yang
authors.initials: ZY
authors.lastname: Sun
authors.forename: He-jie
authors.initials: HJ
authors.lastname: Hu
authors.forename: Ge-liang
authors.initials: GL
authors.lastname: Xu
authors.forename: Jiong
authors.initials: J
authors.lastname: Chen
authors.forename: Jian-sheng
authors.initials: JS
authors.lastname: Li
mesh_terms: D000230:Adenocarcinoma / Q000378:metabolism / Q000473:pathology / Q000601:surgery; D000328:Adult; D000368:Aged; D014408:Biomarkers, Tumor; D002291:Carcinoma, Papillary / Q000378:metabolism* / Q000473:pathology / Q000601:surgery; D005260:Female; D005500:Follow-Up Studies; D015972:Gene Expression Regulation, Neoplastic; D006023:Glycoproteins / Q000235:genetics / Q000378:metabolism*; D006801:Humans; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D009361:Neoplasm Invasiveness; D009367:Neoplasm Staging; D010190:Pancreatic Neoplasms / Q000378:metabolism* / Q000473:pathology / Q000601:surgery; D011379:Prognosis; D016016:Proportional Hazards Models; D012333:RNA, Messenger / Q000378:metabolism; D015996:Survival Rate
chemical_list: D014408:Biomarkers, Tumor; D006023:Glycoproteins; D012333:RNA, Messenger; C021240:tissue-factor-pathway inhibitor 2